Axillary Lymph Node Status and neoadjuvant Therapy in HER2-positive Breast Cancer

被引：0
|
作者：
Danzinger, Autoren S. [1 ]
Pfeifer, C. [2 ]
Wimmer, S. [1 ]
Tendl-Schulz, K. [3 ]
Singer, C. F. [1 ]
机构：
[1] Med Univ Wien, Inst Univ Klin Frauenheilkunde 1, Vienna, Austria
[2] Univ Innsbruck, Inst Stat, Innsbruck, Austria
[3] Med Univ Wien, Klin Inst Pathol, Vienna, Austria
来源：
GEBURTSHILFE UND FRAUENHEILKUNDE | 2021年 / 81卷 / 04期
关键词：
D O I：
10.1055/s-0041-1726593
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
16
引用
收藏
页码：E6 / E6
页数：1
相关论文
共 50 条
  • [21] Axillary Response to Neoadjuvant Therapy in Node-Positive, Estrogen Receptor Positive, HER2 Negative Breast Cancer Patients
    Friedman-Eldar, O.
    Ozmen, T.
    Reyes, F. Valle
    Goel, N.
    Tjendra, Y.
    Moller, M.
    Kesmodel, S. B.
    Franceschi, D.
    Avisar, E.
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (SUPPL 1) : S68 - S68
  • [22] Sentinel lymph node biopsy after neoadjuvant chemotherapy predicts pathological axillary lymph node status in breast cancer patients with clinically positive axillary lymph nodes at presentation
    Hiroyuki Takei
    Takashi Yoshida
    Masafumi Kurosumi
    Kenichi Inoue
    Hiroshi Matsumoto
    Yuji Hayashi
    Toru Higuchi
    Sayaka Uchida
    Jun Ninomiya
    Kazuyuki Kubo
    Hanako Oba
    Shigenori Nagai
    Toshio Tabei
    International Journal of Clinical Oncology, 2013, 18 : 547 - 553
  • [23] De-escalating axillary surgery according to neoadjuvant single or dual HER2 blockade in clinically node-positive, HER2-positive breast cancer
    Cha, C.
    Kim, D.
    Lee, J.
    Park, S.
    Bae, S. J.
    Kim, J. Y.
    Ahn, S. G.
    Park, H. S.
    Park, S.
    Kim, S. I.
    Cho, Y. U.
    Jeong, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [24] Predictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant Therapy
    Guiu, S.
    Reynier, M. A. Mouret
    Toure, M.
    Coudert, B.
    JOURNAL OF ONCOLOGY, 2013, 2013
  • [25] Axillary lymph node dissection in triple-negative or HER2-positive breast cancer patients with clinical N2 achieving pathological complete response after neoadjuvant therapy: Is it necessary?
    Guo, Xuhui
    Zhang, Jiao
    Gong, Xilong
    Wang, Jia
    Dai, Hao
    Jiao, Dechuang
    Ling, Rui
    Zhao, Yi
    Yang, Hongjian
    Liu, Yunjiang
    Liu, Ke
    Zhang, Jianguo
    Mao, Dahua
    He, Jianjun
    Yu, Zhigang
    Liu, Yinhua
    Fu, Peifen
    Wang, Jiandong
    Jiang, Hongchuan
    Zhao, Zuowei
    Tian, Xingsong
    Cao, Zhongwei
    Wu, Kejin
    Song, Ailin
    Jin, Feng
    Fan, Zhimin
    Liu, Zhenzhen
    BREAST, 2024, 73
  • [26] Unveiling Neoadjuvant Therapy: Insights and Outlooks for HER2-Positive Early Breast Cancer
    Bischoff, Herve
    Espie, Marc
    Petit, Thierry
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2024, : 1225 - 1237
  • [27] Pathological Axillary Lymph Node Status in HER-2 Receptor Positive and Negative Breast Cancers
    Jeon Hor Chen
    Garima Agrawal
    P. Carpenter
    Rita S. Mehta
    Orhan Nalcioglu
    Min-Ying Su
    Annals of Surgical Oncology, 2008, 15 : 941 - 942
  • [28] Use of MammaTyper® in predicting response to neoadjuvant therapy in HER2-positive breast cancer
    Scatena, C.
    Belcastro, E.
    Marletta, S.
    Tornabene, I.
    Cinacchi, P.
    Fontana, A.
    Martorana, F.
    Vigneri, P.
    Rizzo, A.
    Naccarato, A. G.
    BREAST, 2025, 80 : S78 - S79
  • [29] Immune repertoire and responses to neoadjuvant TCHP therapy in HER2-positive breast cancer
    Shin, Junyoung
    Ham, Baknoon
    Seo, Jeong-Han
    Lee, Sae Byul
    Park, In Ah
    Gong, Gyungyub
    Kim, Sung-Bae
    Lee, Hee Jin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [30] HER2-positive Breast Cancer: MRI-based Optimization of Neoadjuvant Therapy
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (08) : 666 - 666
12345